Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of ost ...
Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis - Denosumab versus Bisphosphonate for osteoporosis in patients with PBC Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of ost ...
Osteoporosis in biopsy-proven primary biliary cirrhosis patients pretreated with bisphosphonate
Discontinue the administration of aredoron acid, risedronic acid, and minodronic acid. Then, 60mg of denosumab will be subcutaneously injected every 6 months for 12 months. All patients will take activated vitamin D. In the case of hypocalcemia, calcium will be administrated appropriately. Continue the administration of bisphosphonate as heretofore. All patients will take activated vitamin D. Discontinue the administration of aredoron acid, risedronic acid, and minodronic acid. Then, 60mg of ...